search
Back to results

Monitoring Medication Adherence in Left Ventricular Assist Device Recipients

Primary Purpose

Heart Failure, Medication Compliance

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
PROTEUS-SENSOR
Sponsored by
Scripps Translational Science Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Heart Failure focused on measuring Telemedicine, Mobile Health

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

- Patients undergoing LVAD implantation for end-stage heart failure or admitted from the out-patient setting

Exclusion Criteria:

  • Unable to consistently consume oral intake
  • Hemodynamic instability defined as hypotension requiring intravenous vasoactive medications or arrhythmias requiring intravenous antiarrhythmics or oral antiarrhythmics for rhythm stabilization
  • Gastrointestinal bleeding requiring intravenous gastric acid secretion inhibitors

Sites / Locations

  • Scripps Health

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

PROTEUS-SENSOR

Arm Description

The current study is a prospective interventional design with a single experimental arm. The intervention consists of two components: an edible sensor and a wearable receiver health monitor.

Outcomes

Primary Outcome Measures

System Performance - Positive Detection Accuracy
Primary outcome measure of system performance will be estimated by the positive detection accuracy, defined as the number of ingestible sensors detected divided by those ingested

Secondary Outcome Measures

Number of Participants With Adverse Events as a Measure of Safety and Tolerability
Specific safety metrics will consist of the following composite outcome: Safety as measured by vital signs Cardiac rhythm monitoring review for arrhythmias LVAD device interrogation for changes in device parameters Implantable cardioverter defibrillator interrogation for arrhythmia occurrence

Full Information

First Posted
November 25, 2014
Last Updated
November 6, 2020
Sponsor
Scripps Translational Science Institute
Collaborators
Scripps Clinic
search

1. Study Identification

Unique Protocol Identification Number
NCT02388386
Brief Title
Monitoring Medication Adherence in Left Ventricular Assist Device Recipients
Official Title
Pilot Study of Wireless Observed Therapy With an Ingestible Micro-Sensor Among Patients With Heart Failure and Left Ventricular Assist Devices
Study Type
Interventional

2. Study Status

Record Verification Date
August 2020
Overall Recruitment Status
Completed
Study Start Date
February 2015 (undefined)
Primary Completion Date
April 2016 (Actual)
Study Completion Date
April 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Scripps Translational Science Institute
Collaborators
Scripps Clinic

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The investigators aim to develop a novel and wireless method for monitoring medication adherence among heart failure patients with left ventricular assist devices (LVADs). Proteus Digital™ has developed an ingestible and bio-absorbable micro-sensor as a strategy to monitor medication compliance. The edible sensor has at its core a silicon-based integrated circuit measuring 1.0 mm x 0.45 mm and is imbedded on a pill. Once ingested, this circuit is activated by gastric acid resulting in an electrochemical redox reaction and an electrical charge that is transmitted to a patch worn over the abdomen and wirelessly to a portable device such as a smart phone. This strategy of medication adherence differs from conventional adherence monitoring including pill counting and patient-recall by precisely tracking medication ingestion.
Detailed Description
The objectives are to assess the efficacy and safety of the Proteus Digital™ micro-sensor in an exploratory investigation among heart failure patients with LVADs. Medication adherence, specifically to anticoagulation is critically important in the post-implant period to maintain LVAD function and to decrease thromboembolic complications; however, commonly results in significant bleeding resulting in significant morbidity and mortality. In addition, the anticipated degree of anticoagulation is unpredictable after LVAD implantation due to factors related to changes in hepatic blood flow and endothelial dysfunction. Enrolling 10 patients will provide results into the function of micro-sensor and to provide a preliminary assessment of sensor-based activity, signal strength and signal duration in LVAD recipients. Participants will be enrolled during an in-patient hospitalization to assess the efficacy and safety of the device in a monitored setting.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Heart Failure, Medication Compliance
Keywords
Telemedicine, Mobile Health

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Actual)

8. Arms, Groups, and Interventions

Arm Title
PROTEUS-SENSOR
Arm Type
Experimental
Arm Description
The current study is a prospective interventional design with a single experimental arm. The intervention consists of two components: an edible sensor and a wearable receiver health monitor.
Intervention Type
Device
Intervention Name(s)
PROTEUS-SENSOR
Intervention Description
An edible sensor system, Proteus Digital™ has been developed for electronically confirming medication adherence, gathering physiologic metrics and communicating these data to patients. The system consists of two major components: an edible sensor and a wearable receiver health monitor. An electrical signal is activated upon ingestion of the Proteus Digital micro-sensor with transmission of this signal to a receiving abdominal patch to quantify medication compliance.
Primary Outcome Measure Information:
Title
System Performance - Positive Detection Accuracy
Description
Primary outcome measure of system performance will be estimated by the positive detection accuracy, defined as the number of ingestible sensors detected divided by those ingested
Time Frame
30 minutes after ingestion
Secondary Outcome Measure Information:
Title
Number of Participants With Adverse Events as a Measure of Safety and Tolerability
Description
Specific safety metrics will consist of the following composite outcome: Safety as measured by vital signs Cardiac rhythm monitoring review for arrhythmias LVAD device interrogation for changes in device parameters Implantable cardioverter defibrillator interrogation for arrhythmia occurrence
Time Frame
From time of ingestion to 30 minutes after ingestion

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: - Patients undergoing LVAD implantation for end-stage heart failure or admitted from the out-patient setting Exclusion Criteria: Unable to consistently consume oral intake Hemodynamic instability defined as hypotension requiring intravenous vasoactive medications or arrhythmias requiring intravenous antiarrhythmics or oral antiarrhythmics for rhythm stabilization Gastrointestinal bleeding requiring intravenous gastric acid secretion inhibitors
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sanjeev Bhavnani, MD
Organizational Affiliation
Scripps Clinic
Official's Role
Principal Investigator
Facility Information:
Facility Name
Scripps Health
City
San Diego
State/Province
California
ZIP/Postal Code
92037
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Data will be made available upon request
Citations:
PubMed Identifier
26873093
Citation
Bhavnani SP, Narula J, Sengupta PP. Mobile technology and the digitization of healthcare. Eur Heart J. 2016 May 7;37(18):1428-38. doi: 10.1093/eurheartj/ehv770. Epub 2016 Feb 11.
Results Reference
background
PubMed Identifier
26890041
Citation
DiCarlo LA, Weinstein RL, Morimoto CB, Savage GM, Moon GL, Au-Yeung K, Kim YA. Patient-Centered Home Care Using Digital Medicine and Telemetric Data for Hypertension: Feasibility and Acceptability of Objective Ambulatory Assessment. J Clin Hypertens (Greenwich). 2016 Sep;18(9):901-6. doi: 10.1111/jch.12787. Epub 2016 Feb 18.
Results Reference
background
PubMed Identifier
23014703
Citation
DiCarlo L, Moon G, Intondi A, Duck R, Frank J, Hafazi H, Behzadi Y, Robertson T, Costello B, Savage G, Zdeblick M. A digital health solution for using and managing medications: wirelessly observed therapy. IEEE Pulse. 2012 Sep-Oct;3(5):23-6. doi: 10.1109/MPUL.2012.2205777.
Results Reference
background
PubMed Identifier
26721413
Citation
Browne SH, Behzadi Y, Littlewort G. Let Visuals Tell the Story: Medication Adherence in Patients with Type II Diabetes Captured by a Novel Ingestion Sensor Platform. JMIR Mhealth Uhealth. 2015 Dec 31;3(4):e108. doi: 10.2196/mhealth.4292.
Results Reference
background

Learn more about this trial

Monitoring Medication Adherence in Left Ventricular Assist Device Recipients

We'll reach out to this number within 24 hrs